Accelerating scientific discovery to bring life-changing treatments closer to patients
Helping Scientists Choose Better Drug Targets, Faster
Developing new medicines starts with understanding what causes a disease and where treatments might work. Choosing the wrong direction can cost years of research.
BioNexus AI helps scientists make better decisions, faster by bringing together genetic evidence, scientific studies, and clinical trial data to identify promising opportunities, uncover risks, and focus research on treatments that could improve and save lives.
Where BioNexus fits
Picking the right target is where every new medicine begins
A target is a gene or protein that plays a part in a disease. Picking the wrong one is a common reason drugs fail in human trials. Clues from people’s own genes are one of the best early signs that a target is the right one, and targets with that support succeed more often.
- Unmet needA disease without a good treatment
- Find the genesWhich genes and proteins are involved?BioNexus helps at this step.
- Choose a targetPick the most promising oneBioNexus helps at this step.
- Lab studiesTest it in cells and animals
- Clinical trialsTest it in people
- A medicineApproved for patients
What goes wrong
Bad evidence is costly in three ways
Time lost on weak leads
Lots of database hits can make a target look well supported when only a few studies truly back it.
No clear source
When someone asks where a claim came from, nobody can quickly show it.
Problems found too late
Conflicting or missing evidence is easy to miss, and costly to find after the decision.
Impact, honestly stated
What we have measured, and what a pilot will measure next
Measured so far
- A first sourced draft for two genes in about 20 seconds, from five live databases.
- Repeated studies merged across databases (in a live COVID-19 run, 44 records became 39 distinct studies).
- Every excluded record listed with its reason.
- Every report records the models, skills and data versions behind it.
Still to be measured in a pilot
- Scientist hours saved compared with a manual search.
- How often it finds all the evidence an expert would, and how often its citations hold up on expert review.
- Whether the multi-agent team beats a simpler single-agent approach at equal cost.
How it works
A coordinated team, with every handoff recorded
From question to approved report in eight visible steps
Confirms the question is complete and within pilot limits.
Reuses evidence your team already reviewed in this project (never unreviewed work).
Specialist agents query genetics, literature, pathway and trial sources in parallel.
A critic looks for contradictions and missing support and asks specialists to fix what it can.
Ranks the accepted evidence for your question and maps how it connects.
Drafts claims that cite only accepted evidence. No causal or treatment statements.
Assembles the draft report and a reproducibility record.
Waits for a scientist to review and approve one exact report version.
Who it is for
Research scientists, translational and target-discovery teams, and reviewers who need a fast, sourced starting point and want to see how a conclusion was reached.
What it is not
A research aid, not a clinical tool. It does not diagnose, recommend treatments for a person, accept patient records, or prove that a gene causes a disease. Counts and scores guide judgement; they are not probabilities.
Our aim
Accelerating scientific discovery to bring new treatments closer to patients
Sign in, create a project, pick a disease and a few genes, and watch the agent team build a draft you can review.
Start an investigation